Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas

NCT03181100 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03181100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03181100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 27, 2017
Completion date
July 31, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic thyroid gland carcinoma, poorly differentiated thyroid gland carcinoma, stage iva thyroid gland anaplastic carcinoma ajcc v8, stage ivb thyroid gland anaplastic carcinoma ajcc v8, stage ivc thyroid gland anaplastic carcinoma ajcc v8, thyroid gland anaplastic carcinoma, unresectable thyroid gland carcinoma